The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada has issued a Notice of Compliance with Conditions approving RYBREVANT®, a fully-human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic NSCLC.
[Janssen Pharmaceutical Companies]
Sorry, but the selected Zotpress account can't be found.